Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Active Measures To Increase XRP Price. Here’s the Latest

Active Measures To Increase XRP Price. Here’s the Latest

TimesTabloidTimesTabloid2026/10/08 15:00

That is a significant statement. Most corporate treasury vehicles accumulate an asset and wait. Evernorth has committed to something more deliberate.

Details From the Research

The SBI slide confirms that Evernorth has two active tools in its strategy. The first is lending for institutional investors. The second is leveraging DeFi. This is documented directly in SBI’s own materials.

SBI Group invested $200 million in cash into Evernorth through a Private Investment in Public Equity (PIPE). The slide showing these details comes from SBI’s own reporting on that investment, not speculation from outside observers. It is Evernorth’s stated strategy, documented by one of its largest backers.

Digital Asset Investor Weighs In

Digital Asset Investor zeroed in on the same detail SMQKE highlighted. “You’re not creating an XRP treasury unless you’re expecting the value of XRP to go up,” he said, “and expecting to do everything you can to make the value go up.”

He made clear that the active measures language matters. An institution raising over $1 billion to hold a single asset, and committing publicly to grow that asset’s value through lending and DeFi, is sending a clear signal about its expectations for XRP.

Evernorth currently holds 473 million XRP tokens. That figure alone makes it one of the largest public XRP treasury companies in existence. The active strategy SMQKE highlighted applies to that entire position. Institutional lending and DeFi deployment will work off that base, with yields reinvested into additional XRP purchases.

The Nasdaq Date

Evernorth’s Nasdaq debut is now set for on or about October 12, under the ticker XRPN. A brief administrative delay pushed the closing date to on or about October 9. The delay has no expected impact on the transaction closing.

Shareholders approved the merger on September 30. Once trading begins, retail and institutional investors gain regulated access to XRP exposure through a standard brokerage account. The combination of the imminent listing and Evernorth’s publicly documented active strategy gives the XRP community a concrete timeline and a clear mandate to point to.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data

On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)

路透社•2026/10/08 18:26